Abstract:Abstract Zika virus (ZIKV) is an arbovirus from the Flaviviridae family and Flavivirus genus. Neurological events have been associated with ZIKV-infected individuals, such as Guillain-Barré syndrome, an autoimmune acute neuropathy that causes nerve demyelination and can induce paralysis. With the increase of ZIKV infection incidence in 2015, malformation and microcephaly cases in newborns have grown considerably, which suggested congenital transmission. Therefore, the development of an effective vaccine against ZIKV became an urgent need. Live attenuated vaccines present some theoretical risks for administration in pregnant women. Thus, we developed an in silico multiepitope vaccine against ZIKV. All structural and non-structural proteins were investigated using immunoinformatics tools designed for the prediction of CD4 + and CD8 + T cell epitopes. We selected 13 CD8 + and 12 CD4 + T cell epitopes considering parameters such as binding affinity to HLA class I and II molecules, promiscuity based on the number of different HLA alleles that bind to the epitopes, and immunogenicity. ZIKV Envelope protein domain III (EDIII) was added to the vaccine construct, creating a hybrid protein domain-multiepitope vaccine. Three high scoring continuous and two discontinuous B cell epitopes were found in EDIII. Aiming to increase the candidate vaccine antigenicity even further, we tested secondary and tertiary structures and physicochemical parameters of the vaccine conjugated to four different protein adjuvants: flagellin, 50S ribosomal protein L7/L12, heparin-binding hemagglutinin, or RS09 synthetic peptide. The addition of the flagellin adjuvant increased the vaccine's predicted antigenicity. In silico predictions revealed that the protein is a probable antigen, non-allergenic and predicted to be stable. The vaccine’s average population coverage is estimated to be 87.86%, which indicates it can be administered worldwide. Peripheral Blood Mononuclear Cells (PBMC) of individuals with previous ZIKV infection were tested for cytokine production in response to the pool of CD4 and CD8 ZIKV peptide selected. CD4 + and CD8 + T cells showed significant production of IFN-γ upon stimulation and IL-2 production was also detected by CD8 + T cells, which indicated the potential of our peptides to be recognized by specific T cells and induce immune response. In conclusion, we developed an in silico universal vaccine predicted to induce broad and high-coverage cellular and humoral immune responses against ZIKV, which can be a good candidate for posterior in vivo validation.

Corrigendum: Enhanced immunogenicity and protective efficacy in mice following a Zika DNA vaccine designed by modulation of membrane-anchoring regions and its association to adjuvants

Corrigendum: Advancement in the Development of Therapeutics Against Zika Virus Infection

Addition of nucleotide adjuvants enhances the immunogenicity of a recombinant subunit vaccine against the Zika virus in BALB/c mice

Corrigendum: A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice

Vaccine protection against Zika virus from Brazil

Corrigendum to “antibacterial Coaxial Hydro-Membranes Accelerate Diabetic Wound Healing by Tuning Surface Immunomodulatory Functions” [mater. Today Bio, 16 (2022)]

Corrigendum: Chaperones, Membrane Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus Trvlps and Interact with Trvlp Elements.

Correction: Corrigendum: the Changing Shape of Vaccination: Improving Immune Responses Through Geometrical Variations of a Microdevice for Immunization

Correction: Cao et al. Effective Functional Immunogenicity of a DNA Vaccine Combination Delivered via In Vivo Electroporation Targeting Malaria Infection and Transmission. Vaccines 2022, 10, 1134

A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models

Erratum: Virus-like particles are efficient tools for boosting mRNA-induced antibodies

In silico construction of a multiepitope Zika virus vaccine using immunoinformatics tools

Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine

Immunization against Zika by entrapping live virus in a subcutaneous self-adjuvanting hydrogel

An immunoinformatics and structural vaccinology approach to design a novel and potent multi-epitope base vaccine targeting Zika virus

Bovine serum albumin nanoparticles containing Poly (I:C) can enhance the neutralizing antibody response induced by envelope protein of Orthoflavivirus zikaense

Corrigendum: Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV

Corrigendum: Polymorphisms in Genes Affecting Interferon-γ Production and Th1 T Cell Differentiation Are Associated With Progression to Chagas Disease Cardiomyopathy

Corrigendum: Mind the “vaccine fatigue”

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Exploring the immunogenicity of an insect-specific virus vectored Zika vaccine candidate